The trial, run by the HIV Vaccines Trial Network (HVTN) and HIV Prevention Trials Network (HPTN), will evaluate the safety, dosing, pharmacokinetics, and ability of four bnAbs to neutralize HIV.
IAVI news release
IAVI announced the use of its broadly neutralizing antibody (bnAb), ePGT121v1-LS, in a first-in-human, Phase 1 clinical trial that began on March 19, 2026. IAVI’s HIV bnAbs program is designed to develop efficacious antibodies that can prevent HIV transmission. The program is specifically geared for eventual use to prevent HIV transmission to infants during the post-natal period. With 120,000 children newly acquiring HIV in 2024 alone, and 50 percent of infant HIV acquisition taking place in the breastfeeding period, there is a clear need for additional prevention tools developed to protect this vulnerable population. The onset of this clinical trial is a significant step in examining whether a combination of broadly neutralizing antibodies could be this new tool. With robust safety and dose data collected through this study, which has only adult participants, IAVI’s team will have the necessary data to plan future studies in infants.
Read the full news release here.
Source : IAVI
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.